NCT04616846View on ClinicalTrials.gov

Thromboembolic Risk Screening in Patients With Cancer and COVID-19

NACompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

January 25, 2022

Study Completion Date

January 25, 2022

Conditions
Neoplasms MalignantCovid19Thromboembolism
Interventions
DIAGNOSTIC_TEST

Peripheral venous ultrasound

Screening for VTE from D7 to 42

Trial Locations (6)

98000

CHPG, Monaco

06800

Clinique Saint-Jean, Cagnes-sur-Mer

06250

Centre Azuréen de Cancérologie, Mougins

06000

CHU Nice, Nice

06105

Clinique Saint-Georges, Nice

06189

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

Centre Antoine Lacassagne

OTHER

NCT04616846 - Thromboembolic Risk Screening in Patients With Cancer and COVID-19 | Biotech Hunter | Biotech Hunter